Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

Researchers at McGill University and the Douglas Institute have identified two specific types of brain cells that are altered in people with depression.

The study, published in Nature Genetics, opens the door to developing new treatments that target these cells and deepens our understanding of depression, a leading cause of disability worldwide that affects more than 264 million people.

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to:

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

This competition is open to: